crizotinib and Liver-Failure--Acute

Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biomarkers; Crizotinib; Gene Rearrangement; Humans; Liver Failure, Acute; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors

Herein we describe a case of a 62-year-old female in good clinical condition with non-small-cell lung cancer who was treated with crizotinib. After 24 days of crizotinib therapy she presented with acute liver failure. Serum aspartate aminotransferase and alanine aminotransferase levels had increased from normal prior to crizotinib start to 2053 IU/L and 6194 IU/L, respectively. Total bilirubin and prothrombin time (PT-INR) increased up to 443 IU/L and 5.33, respectively, and symptoms of hepatic encephalopathy and hepatorenal syndrome emerged. Despite crizotinib discontinuation and intensive supportive therapy, the patient died 40 days after treatment with crizotinib was initiated due to acute liver failure with massive liver cell necrosis.

Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Crizotinib; Fatal Outcome; Female; Humans; Liver Failure, Acute; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Pyridines